Literature DB >> 23837912

Keap calm, and carry on covalently.

Anthony J Wilson1, Jeffrey K Kerns, James F Callahan, Christopher J Moody.   

Abstract

The Nrf2-Keap1 system plays a major role in cellular defense against oxidative stress. Upon exposure to electrophiles, the cysteine-rich protein Keap1 is covalently modified, and it is this modification of Keap1 that allows the accumulation and subsequent nuclear translocation of Nrf2 where it induces the transcription of over 100 protective genes. This mechanism can be exploited in drug discovery approaches to diseases such as chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), asthma, and neurodegenerative diseases like multiple sclerosis (MS) and Parkinson's, utilizing the modification of Keap1 by electrophiles, compounds that would not normally be considered useful in drug discovery programs. This Perspective discusses the development of potential therapies based on potent electrophiles, such as isothiocyanates and Michael acceptors, that, far from being associated with toxic events, can actually initiate a range of beneficial protective pathways.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23837912     DOI: 10.1021/jm400224q

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  28 in total

Review 1.  No quiet surrender: molecular guardians in multiple sclerosis brain.

Authors:  Lawrence Steinman
Journal:  J Clin Invest       Date:  2015-04-01       Impact factor: 14.808

Review 2.  Non-electrophilic modulators of the canonical Keap1/Nrf2 pathway.

Authors:  B G Richardson; A D Jain; T E Speltz; T W Moore
Journal:  Bioorg Med Chem Lett       Date:  2015-04-16       Impact factor: 2.823

Review 3.  Small molecules inhibiting Keap1-Nrf2 protein-protein interactions: a novel approach to activate Nrf2 function.

Authors:  Chunlin Zhuang; Zhongli Wu; Chengguo Xing; Zhenyuan Miao
Journal:  Medchemcomm       Date:  2016-11-17       Impact factor: 3.597

4.  Targeted Covalent Inhibition of Telomerase.

Authors:  Rick C Betori; Yue Liu; Rama K Mishra; Scott B Cohen; Stephen J Kron; Karl A Scheidt
Journal:  ACS Chem Biol       Date:  2020-02-24       Impact factor: 5.100

5.  NRF2-targeted therapeutics: New targets and modes of NRF2 regulation.

Authors:  Montserrat Rojo de la Vega; Matthew Dodson; Eli Chapman; Donna D Zhang
Journal:  Curr Opin Toxicol       Date:  2016-10-12

6.  Regio- and Stereospecific Synthesis of Oridonin D-Ring Aziridinated Analogues for the Treatment of Triple-Negative Breast Cancer via Mediated Irreversible Covalent Warheads.

Authors:  Ye Ding; Dengfeng Li; Chunyong Ding; Pingyuan Wang; Zhiqing Liu; Eric A Wold; Na Ye; Haiying Chen; Mark A White; Qiang Shen; Jia Zhou
Journal:  J Med Chem       Date:  2018-03-20       Impact factor: 7.446

7.  Polar Recognition Group Study of Keap1-Nrf2 Protein-Protein Interaction Inhibitors.

Authors:  Meng-Chen Lu; Shi-Jie Tan; Jian-Ai Ji; Zhi-Yun Chen; Zhen-Wei Yuan; Qi-Dong You; Zheng-Yu Jiang
Journal:  ACS Med Chem Lett       Date:  2016-07-05       Impact factor: 4.345

Review 8.  Tetrazoles via Multicomponent Reactions.

Authors:  Constantinos G Neochoritis; Ting Zhao; Alexander Dömling
Journal:  Chem Rev       Date:  2019-02-01       Impact factor: 60.622

9.  Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators.

Authors:  Atul D Jain; Haranatha Potteti; Benjamin G Richardson; Laura Kingsley; Julia P Luciano; Aya F Ryuzoji; Hyun Lee; Aleksej Krunic; Andrew D Mesecar; Sekhar P Reddy; Terry W Moore
Journal:  Eur J Med Chem       Date:  2015-09-04       Impact factor: 6.514

10.  Ang(1-7) exerts Nrf2-mediated neuroprotection against amyloid beta-induced cognitive deficits in rodents.

Authors:  Vibhav Varshney; Debapriya Garabadu
Journal:  Mol Biol Rep       Date:  2021-06-01       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.